Weight-loss medicines: Biocon eyes a $100 billion jackpot with weighty pivot

Weight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in generic supply. The Bengaluru-based company secured UK approval for the first generic version of liraglutide injectible, positioning itself as a leader in this evolving market.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news